Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immuneering Corp Cl A (NQ: IMRX )

9.710 -0.250 (-2.51%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 43,059
Open 9.860
Bid (Size) 3.860 (2)
Ask (Size) 10.00 (6)
Prev. Close 9.960
Today's Range 9.080 - 10.46
52wk Range 3.700 - 16.17
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2023
 
Via Benzinga
Immuneering Appoints Harold E. Brakewood as Chief Business Officer
Seasoned biopharma executive with global business development, commercialization, and new product planning expertise to support the development of a universal-RAS franchise 
From Immuneering Corporation
Via Globe NewsWire

Performance

YTD
+142.14%
+142.14%
1 Month
+93.81%
+93.81%
3 Month
+142.14%
+142.14%
6 Month
-35.09%
-35.09%
1 Year
+30.51%
+30.51%

More News

Read More
Why Shares of Immuneering Jumped This Week
Via The Motley Fool
Looking Into Immuneering's Return On Capital Employed
Via Benzinga
Immuneering Earnings Preview
Via Benzinga
Immuneering's Return On Capital Employed Insights
Via Benzinga
Immuneering to Present Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023
From Immuneering Corporation
Via Globe NewsWire
Top 5 Health Care Stocks That Are Ticking Portfolio Bombs
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Immuneering Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
From Immuneering Corporation
Via Globe NewsWire
Immuneering Presents Preclinical Data with Lead Program IMM-1-104 Supporting Universal-RAS Activity
From Immuneering Corporation
Via Globe NewsWire
Immuneering Announces Participation in March Investor Conferences
From Immuneering Corporation
Via Globe NewsWire
Immuneering to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates
From Immuneering Corporation
Via Globe NewsWire
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023
Via Benzinga
Immuneering To Present at Guggenheim 2023 Oncology Conference
From Immuneering Corporation
Via Globe NewsWire
Immuneering Announces First Patient Dosed in its Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations
From Immuneering Corporation
Via Globe NewsWire
Immuneering Presents Promising Preclinical Data on its Second Program IMM-6-415 at the 37th Annual Meeting of SITC
From Immuneering Corporation
Via Globe NewsWire
Immuneering Reports Third Quarter 2022 Financial Results and Recent Business Highlights
From Immuneering Corporation
Via Globe NewsWire
Immuneering Announces Participation in November Investor Conferences
From Immuneering Corporation
Via Globe NewsWire
Immuneering Appoints Leah R. Neufeld as Chief People Officer
From Immuneering Corporation
Via Globe NewsWire
Immuneering To Present Poster on IMM-6-415 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
From Immuneering Corporation
Via Globe NewsWire
Why Carnival Shares Are Trading Lower By 19%, Here Are 49 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Why F45 Training Shares Climbed 41%; Here Are 84 Biggest Movers From Friday
Via Benzinga
Micron, Charles River Laboratories And Some Other Big Stocks Moving Higher On Friday
Via Benzinga
Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations
From Immuneering Corporation
Via Globe NewsWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.